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Paired helical filaments (PHF) are the principal
pathologic components of neurofibrillary tangles in Alz-
heimer’s disease (AD). To reproduce the formation of
PHF in tissue culture, we stably expressed human tau
with and without pathogenic mutations in human SH-
SY5Y cells and exposed them for 5 days to aggregated
synthetic -amyloid peptide (A42). This caused a de-
creased solubility of tau along with the generation of
PHF-like tau-containing filaments. These were 20 nm
wide and had periodicities of 130–140 nm in the pres-
ence of P301L mutant tau or 150–160 nm in the presence
of wild-type tau. Mutagenesis of the phosphoepitope
serine 422 of tau prevented both the A42-mediated
decrease in solubility and the generation of PHF-like
filaments, suggesting a role of serine 422 or its phospho-
rylation in tau filament formation. Together, our data
underscore a role of A42 in the formation of PHF-like
filaments. Our culture system will be useful to map
phosphoepitopes of tau involved in PHF formation and
to identify and characterize modifiers of the tau pathol-
ogy. Further adaptation of the system may allow the
screening and validation of compounds designed to pre-
vent PHF formation.
Neurofibrillary tangles (NFT)1 are abundant in many neu-
rodegenerative diseases, including Alzheimer’s disease (AD)
and frontotemporal dementia with Parkinsonism linked to
chromosome 17 (FTDP-17) caused by mutations in the tau gene
(1–3). NFT are composed of filamentous aggregates that in-
clude paired helical filaments (PHF) and narrow twisted rib-
bons. These are made of the microtubule-associated protein tau
(4, 5). Tau in these filaments is hyperphosphorylated both at
physiological sites and at additional, pathological sites. Phos-
phorylation of tau is associated with the dissociation of tau
from microtubules and with its relocalization from axons to cell
bodies and dendrites. Pathologic increases in this pool of solu-
ble tau, along with conformational changes of the natively
unfolded tau, are initial critical steps in the assembly of the
more insoluble pathological tau filaments.
Transgenic mice expressing pathogenic mutations of human
tau generate a few low abundant NFT (6, 7), and both intrac-
erebral microinjections of -amyloid into P301L mutant tau
transgenic mice and co-expression of mutant amyloid precursor
protein greatly accelerate the rate of NFT formation in mice (8,
9). These data established a mechanistic relationship of -amy-
loid toxicity with NFT formation.
To circumvent the inherent limitations of the above in vivo
experiments (including poor breeding of doubly transgenic mice
as well as stereotaxic techniques) and to establish PHF forma-
tion in tissue culture, we expressed both wild-type and mutant
forms of human tau in human SH-SY5Y cells and exposed them
to preparations of aggregated synthetic -amyloid. We were
able to produce bona fide PHF-like tau filaments within 5 days
of tissue culture.
EXPERIMENTAL PROCEDURES
Site-directed Mutagenesis—The longest human 4-repeat tau isoform,
htau40, was cloned into the pRc/RSV expression vector (Invitrogen).
Site-directed mutagenesis (QuikChange kit; Stratagene) was performed
to generate the tau mutant P301L and the double mutants, P301L/
S422E and P301L/S422A. The sequences of the mutagenized oligonu-
cleotides were as follows: P301L, 5-GGTTTGTAGACTATTTGCAC-
ACTGCCGCCTCCCTGGACGTGTTTG-3; S422E, 5-GCATCGACAT-
GGTAGACGAGCCCCAGCTCGCCACGC-3; S422A, 5-GCATCGA-
CATGGTAGACGCGCCCCAGCTCGCCACGC-3. All constructs were
sequenced to confirm the absence of randomly introduced mutations.
Cell Culture—Human SH-SY5Y neuroblastoma cells were trans-
fected with either wild-type or mutant htau40 cDNA constructs using
LipofectAMINE 2000 (Invitrogen) and selected with 125 g/ml G418 for
30 days. Pools of selected clones were seeded at a density of 0.3–2.0 
104 cells/cm2, depending on the type of experiment (low density culture
for immunocytochemistry and high density culture for electron micros-
copy and Western blot analysis). To normalize for cell numbers, undif-
ferentiated cells were seeded at a density which, after A42 incubation
for 5 days, was below 50% and thus comparable with numbers of
differentiated cells at the time of A42 treatment. To induce neuronal
differentiation, cells were seeded on collagen type I-coated dishes and
treated with 20 M all-trans-retinoic acid (Sigma) for 5 days in standard
culture medium and cultivated for an additional 5 days in serum-free
medium complemented with 50 ng/ml brain-derived neurotrophic factor
(Peprotech, Lucerne, Switzerland) (10).
Neuronal properties were confirmed by the presence of neuronal
markers and the absence of glial markers (data not shown). Moreover,
the cells expressed synaptophysin when cultured on murine organo-
typic hippocampal slices.2 Two independent lots of A42 (Nos. 524548
and 535120) and A42–1 (Lot No. 536763) were synthesized by Bachem
(Bubendorf, Switzerland), reconstituted in PBS at calculated concen-
trations of 220 M, shaken at 1000 rpm for 24 h at 37 °C, and analyzed
by electron microscopy. This preparation contained -amyloid fibrils
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along with protofibrils and SDS-stable oligomers (11). Suspensions of
A42 preparations corresponding to 10 M soluble peptide were added to
each culture for 1–5 days for immunohistochemistry or 2–5 days for
sarkosyl extractions and electron microscopy. Once A42 preparations
had been added to the cells, the medium was not changed. This, in
addition to the stickiness of A42, may explain why A42 formed large
clumps on the cells as visualized by immunocytochemistry and electron
microscopy. Lactate dehydrogenase assays (Sigma) were performed to
measure the toxicity of A42.
Immunofluorescence Analysis and Antibodies—For immunocyto-
chemistry, cells were grown on collagen-coated coverslips and fixed
with 4% paraformaldehyde in microtubule-stabilizing buffer at room
temperature for 30 min, followed by permeabilization with 0.3% Triton
X-100. The following antibodies were used for immunocytochemistry
(IC), Western blotting (WB), and electron microscopy (EM): HT7 (Inno-
genetics Inc, Belgium; amino acids 159–163; IC, 1:300; WB, 1:300) and
Tau-5A6 (Developmental Studies Hybridoma Bank; EM, 1:50) (12) were
used to specifically detect human tau. Antisera Ser422P 988 (Dr. Andre
Delacourte; IC: 1:1000) (13), and pS422 (BIOSOURCE Inc., Nivelles,
Belgium; IC, 1:1000) were used to detect tau phosphorylated at Ser-422.
Antibodies for neuronal markers included NF200 (Sigma; IH, 1:400),
NSE (Dako, Glostrup, Denmark; IC, 1:200), and MAP2 (Chemicon,
Temecula, CA; IC, 1:400), and as a glial marker GFAP (Sigma; IC,
1:100) was used. Monoclonal antibody 4G8 (Signet Laboratories, Ded-
ham, MA; IC, 1:500; EM, 1:50) was used to detect A amyloid peptide.
Secondary antibodies for immunofluorescence were obtained from Jack-
son Laboratories (West Grove, PA). For a quantification, two independ-
ent experiments were performed and 200 cells were counted for each
experimental condition.
Western Blot Analysis, A-ELISA, and Quantitative RT-PCR—Tau-
expressing cells were grown on 10-cm dishes and extracted in RIPA
buffer as described previously (14). Proteins were separated on a 10%
NuPAGE gel (Invitrogen), blotted onto a nitrocellulose membrane, and
probed with HT7 and a -actin-specific antibody (Abcam, Cambridge,
UK; 1:5000).
The levels and solubility of tau protein were determined by extract-
ing A-treated and control cells using buffers with increasing ionic
strengths (14). The cells were homogenized in high-salt reassembly
(RAB) buffer to generate the RAB-insoluble fractions. Following cen-
trifugation, the pellets were homogenized in RIPA buffer and centri-
fuged. The RIPA-insoluble pellets were extracted with 70% formic acid
(FA) to give the FA fractions. Centrifugation was done at 50,000  g for
20 min. Protein concentrations of the samples from each fraction were
adjusted to equal levels and the same amounts of protein run on a 10%
NUPAGE gel and blotted as described above. As loading control and to
exclude contamination of the FA fraction with soluble proteins, the
blots were probed with a GAPDH-specific monoclonal antibody (BioDe-
sign, Saco, ME; 1:500). Furthermore, an A42-specific ELISA (Innoge-
netics, Gent, Belgium) was included for a subset of the samples.
For quantification, the Western blots were probed with the tau-
specific antibody HT7 and analyzed by densitometry. The same expo-
sure time was chosen for all blots. The x-ray films were scanned at 400
ppi and the images analyzed with the AlphaEase software (Alpha
Innotech Corp., San Leandro, CA). For the purpose of graphic repre-
sentation, for each blot the intensity values of all time points were
normalized using the value at time point t 0. Statistical analysis of the
intensity differences between PBS- and A42-treated samples was done
with the original intensity values, because only the relative and not the
absolute differences are relevant for the two-tailed Student’s t test.
The real-time quantitative PCR for tau was done with HPLC-puri-
fied primers and an HPLC-purified probe (forward primer, 5-CAA-
GACCAAGAGGGTGACACG-3; reverse primer, 5-TCAGAGCCCGGT-
TCCTCAG-3 (Metabion GmbH, Martinsried, Germany); TaqMan
probe, 5-6-FAM-CTGGCCTGAAAGAATCTCCCCTGCA-BHQ-1–3
(Biosearch Technologies Inc., Novato, CA). As reference gene, the Taq-
Man rodent GAPDH control no. 4308313 (Applied Biosystems,
PerkinElmer Life Sciences) was used and Ct values (cycle threshold
values) were determined.
Sarkosyl Extraction and Immunoelectron Microscopy—Sarkosyl ex-
tractions of tau were done as previously described (15). The extracts
were placed on formvar/carbon-coated 300-mesh grids and incubated
with the primary antibody in PBS/0.1% gelatin for 90 min at room
temperature. Antibody Tau-5A6 was used at a 1:50 dilution. As a
positive control, AD brain extracts were included; the secondary anti-
body used for AD extracts was either conjugated to gold (data not
shown) or not (for Fig. 4). In addition, extracts were incubated with the
A42-specific antibody 4G8 at 1:50 dilutions. Again, controls were in-
cluded in which the primary antibody had been omitted. Grids were
incubated with 6 nm Au-conjugated or unconjugated secondary anti-
bodies (Aurion, Wageningen, Netherlands) and stained with 2% phos-
photungstic acid. Micrographs were recorded on a Philips model CM12
electron microscope.
Thin Section Immunoelectron Microscopy—To visualize -amyloid on
the cells, samples were fixed in 4% paraformaldehyde and 0.1% glut-
araldehyde. Following fixation, tissue blocks were epoxy-embedded,
sectioned with a Reichert Ultracut E microtome (Leica, Solms, Germa-
ny), placed on 200-mesh copper grids, and stained with uranyl acetate
and lead citrate. To visualize tau filaments, cells were fixed in 3%
paraformaldehyde and 0.1% glutaraldehyde for 30 min at room tem-
perature, washed with 50 mM NH4Cl in PBS, embedded in 3% agar
(Noble; Difco Laboratories, Detroit, MI), and submerged in sucrose-PVP
2 M (Sigma) for 3 days. Samples were mounted and cut on a Reichert
Ultracut S cryostat (Leica) to obtain ultra-thin sections. Grids were
processed for immunolabeling as follows. After a blocking step in 5%
goat serum in PBS for 20 min, the primary anti-tau antibody Tau-5A6
was added in 1% goat serum in PBS at a 1:50 dilution for 2 h, followed
by a 6-nm gold-coupled goat anti-mouse antiserum (Aurion) in 1%
bovine serum albumin in PBS at a 1:5 dilution for 1 h. Controls were
included in which the primary antibody had been omitted. Washes were
done with 1% bovine serum albumin in PBS for 10 min. Finally, the
grids were stained with 3% uranyl acetate and 2% methylcellulose.
Micrographs were recorded on a Philips model CM12 electron micro-
scope. To determine the number of gold-decorated tau filamentous
aggregates/cell, a cut-off of 15 gold particles per aggregate was defined,
and groups of gold particles were counted per cell in 30 A42-treated
compared with 30 untreated cells.
RESULTS
A42 Decreases the Solubility of Tau—To assess the role of
A42 in tau aggregation and filament formation in tissue cul-
ture, we added preparations of aggregated synthetic A42 to
the media of SH-SY5Y cells that had been stably transfected
with expression constructs encoding the longest 4-repeat iso-
form of human tau, with or without the pathogenic FTDP-17
mutation P301L (Fig. 1A). Confocal analysis confirmed the
presence of A42 aggregates deposited on both cell bodies and
neurites (Fig. 1B). Neither the size nor the number of these
aggregates varied within 1 and 5 days of incubation. Electron-
microscopic analyses demonstrated that A42 aggregates con-
tained the expected amorphous fibrous material that was sim-
ilar to that extracted from brain -amyloid plaques (Fig. 1,
C–E). In this assay system the initial 5 days of treatment with
A42 were not accompanied by any obvious increases in cell
death, and lactate dehydrogenase (LDH) assays did not reveal
increased LDH release, as compared with vehicle controls (data
not shown).
Western blots confirmed that cellular levels of human tau
were similar in all transfected conditions, both in undifferen-
tiated cells (data not shown) and cells that were sequentially
differentiated with retinoic acid and brain-derived neurotro-
phic factor (Fig. 1A).
To determine the role of A42 in the aggregation of tau, we
used undifferentiated cells that expressed wild-type human
tau. We extracted cellular proteins in high-salt RAB buffer to
generate the RAB fraction. We then homogenized the RAB-
insoluble pellet in RIPA buffer to obtain RIPA-soluble proteins
and extracted the RIPA-insoluble pellet with FA to obtain the
FA-soluble protein fraction (Fig. 2). Equal amounts of total
protein of the treated and untreated fractions were loaded, but
the FA fractions contained less protein than the RAB and RIPA
fractions. The signals in the three fractions could not be added
up to determine the total amount of tau, because tau had been
sequentially extracted. After 1 day of A42 treatment, most tau
was present in the RAB fraction and only a small fraction was
RAB-insoluble and found in the RIPA fraction, as compared
with none in the RIPA fraction of the vehicle-treated cells (Fig.
2A). During 5 days of incubation with A42, the solubility of tau
decreased significantly because a substantial amount of it ap-
peared in the RIPA and FA fractions. In contrast, in untreated
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control cells, tau was absent from the FA fraction after 5 days
of incubation with the vehicle (Fig. 2B). In addition to full-
length tau, we observed, at variable degrees, truncated tau
with a molecular mass of 28 kDa. Probing of the blots (Fig. 2B)
with a GAPDH-specific monoclonal antibody confirmed equal
amounts of protein in the RAB fraction. Moreover, we could
exclude a carryover of soluble proteins into the FA fraction
(Fig. 2C). An A42-specific ELISA (Innogenetics) was included
for a subset of the samples. This assay showed that substantial
amounts of A42 were in the RIPA and FA fraction (data not
shown). Therefore, by loading equal amounts of protein of the
A42- and PBS-treated FA fractions, the amount of FA-soluble
tau is likely to be underestimated in the A42-treated compared
with the PBS-treated FA fractions. Next, to monitor the kinet-
ics of tau assembly, combined levels of FA-soluble full-length
and truncated tau were quantified after incubation with A42
for 0 h, 6 h, 1 d, 3 d, and 5 d and compared with PBS-treated
controls. Three independent experiments revealed an increase
of tau in the FA fraction with longer exposure to A42 that was
statistically significant at 5 d (Fig. 2D, *, two-tailed Student’s t
test; p  0.03).
To determine whether A42 affects tau transcription, we
performed a quantitative RT-PCR analysis. When undifferen-
tiated P301L cells were compared with mock-transfected cells
at time point 0, we found that incubation with A42 for 5 days
did not alter tau mRNA levels, either in mock- or P301L-
transfected cells (Fig. 3).
A42 Induces PHF-like Tau Filaments—To determine
whether the decreased solubility of tau in response to exposure
to A42 was associated with the formation of PHF, we analyzed
sarkosyl protein extracts by negative contrast electron micros-
copy (Fig. 4). As a control, we included sarkosyl extracts from a
human brain with a confirmed NFT pathology. It contained
many PHF with expected widths of 20 nm and periodicities of
75–80 nm (Fig. 4A) (16).
Immunoelectron microscopy of sarkosyl protein extracts of
undifferentiated SH-SY5Y cells expressing wild-type human
tau with the monoclonal antibody Tau-5A6 identified many
twisted filaments with widths of up to 20 nm, periodicities of
150–160 nm, and lengths of up to 1200 nm (Fig. 4, B and C and
Table I). They resembled the PHF extracted from NFT in
human neurodegenerative diseases and are best described as
narrow twisted ribbons (17).
Because the ultrastructural characteristics of abnormal fil-
aments in human neurodegenerative diseases vary with path-
ogenic mutations (4, 5), we analyzed the abnormal filaments
generated by P301L mutant tau. Again, A42 caused the gen-
eration of PHF-like filaments both in differentiated and undif-
ferentiated cells stably transfected with P301L mutant tau
(Fig. 4, D and E and Table I). These PHF had shorter periodi-
cities of 130–140 nm with similar widths as compared with the
FIG. 1. A42 aggregates are deposited on tau-expressing cells.
A, Western blot analysis of neuronally differentiated cells using a
human tau-specific antibody reveals comparable levels of transfected
4-repeat tau in wild-type, P301L, P301L/S422E, and P301L/S422A cells
(arrow). Undifferentiated cells express comparable levels of 4-repeat
tau (data not shown). Levels of 4-repeat tau are more than 10-fold
increased when compared with endogenous 3-repeat tau in the mock-
transfected control cells (arrow). -Actin staining is included to confirm
equal loading. B, confocal analysis of cells shows that A42 (4G8, green)
forms large clumps on the cell bodies and processes of neuronally
differentiated tau-expressing cells (HT7, red). Intracellular accumula-
tion of A42 is not detectable. C, electron microscopy of an A42 deposit
in contact with a cell (low magnification) illustrates the filamentous
structure of A42 in the two boxed areas shown at higher magnification
in panels D and E. The inset in panel E shows sarkosyl-extracted A42
fibrils that are 7–10 nm wide and lack regular periodicities. Scale bar,
20 m (B), 3 m (C), and 40 nm (panel E, inset).
FIG. 2. Solubility of tau in transfected SH-SY5Y cells. A, sequen-
tial extraction of both untreated and A42-treated undifferentiated
wild-type tau-expressing cells in high-salt RAB buffer, RIPA buffer, and
FA already reveals after a 1-day incubation with A42 a small fraction
of tau in the RIPA fraction, in contrast to untreated cells. B, after a
5-day incubation with A42 the solubility of tau is significantly de-
creased as a substantial fraction of tau is present in both the RIPA and
FA fractions, whereas in untreated cells after a 5-day culture period,
tau is present in the RIPA fraction but absent in the FA fraction. C, as
loading control, GAPDH (39 kDa) has been included. D, to monitor the
kinetics of tau insolubility, tau in the FA fraction is shown after incu-
bation with PBS () or A42 (f) for 0 h, 6 h, 1 d, 3 d, and 5 d. For each
experiment, the ratio of the intensities for each time point was deter-
mined relative to the value at time point t 0. Intensity values are given
in percentages. The data represent the mean of three independent
experiments for time points t 6 h, 1 d, and 5 d, and two for t 3 d. A
two-tailed Student’s t test reveals statistically significant differences (*,
p  0.03) after 5 days of incubation with A42.
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wild-type tau filaments, consistent with the fact that mutations
can affect the phenotype of the tau filaments.
To exclude that the PHF-like filaments contained -amyloid
fibrils derived from our A42 preparation, we showed that the
anti-A42 antibody 4G8 failed to decorate the PHF, whereas it
clearly decorated -amyloid fibrils extracted with the identical
sarkosyl protocol (data not shown). Moreover, we found with
electron microscopy that our -amyloid fibrils were 7–10 nm
wide and lacked regular periodicities (Fig. 1E, inset) (11). Con-
trol experiments showed that neither vehicle controls nor iden-
tical preparations of the reverse peptide A42–1 caused the
formation of PHF.
Neuronally differentiated SH-SY5Y cells transfected with
either wild-type or P301L tau also formed many PHF-like
filaments after 5 days of exposure to the A42 preparation
(Table I). This may be because of similar cellular levels of
human tau in both differentiated and undifferentiated cells, in
that cellular levels of tau in the transfected cells exceeded those
of endogenous 3-repeat tau (18) by more than 10 times
(Fig. 1A).
A quantitative analysis of filament formation in sarkosyl
extracts by negative staining electron microscopy is impossible
because the adherence of the sample to the grid surface is
irregular, due to the irreproducibility of the surface charge of
the carbon-coated grids. Thus, filaments may cluster in one
field of a grid, whereas another field may be completely empty.
A semi-quantitative analysis can be achieved by immuno-
electron microscopy on ultra-thin cryosections of cells. We
treated undifferentiated wild-type tau-expressing cells either
with A42 or PBS and obtained cryosections that were incu-
bated with the human tau-specific antibody Tau-5A6, followed
by a gold-labeled secondary antibody. As a control, the primary
antibody was omitted. Cryoelectron microscopy has the disad-
vantage that cellular structures are not resolved, but antibod-
ies can penetrate the sections more easily. Many gold-deco-
rated aggregates were revealed in the cytoplasm of neurons
that were treated with A42 (Fig. 5, A and B). For a quantifi-
cation, an arbitrary cut-off of 15 gold particles was defined to
increase the stringency and to reduce the background. Groups
of gold particles were counted per cell in A42-treated com-
pared with untreated cells. This revealed a strong increase in
the number of tau aggregates in A42-treated cells (Fig. 5C).
Role of Epitope Ser-422 of Tau in Aggregation and Filament
Formation—In transgenic mice expressing P301L tau, Ser-422
was among the epitopes that were selectively phosphorylated
in response to A42 injections (9). Therefore, we stained both
neuronally differentiated P301L and wild-type tau-expressing
cells with the phospho-Ser-422-specific antiserum pS422 and
included the phospho-Ser-202/Thr-205-specific antibody AT8
as a control. 200 cells were counted for each experimental
condition. A42 treatment did not cause increases in the num-
bers of AT8-positive cells; all HT7-positive tau-expressing cells
were also AT8-positive, even in the absence of A42 (data not
shown). In contrast, incubation of P301L-expressing cells with
A42 for 1 day caused a more than 2-fold increase in the
number of pS422-positive cells compared with HT7-positive
cells, whereas wild-type tau-expressing cells required treat-
ment for 5 days with A42 to increase the ratio of pS422-
positive cells (19) (Fig. 6, A–D). This difference was statistically
significant (*, wild-type cells treated with A42 for 5 days:
29.81%  7.04% pS422-positive cells/HT7-positive cells; wild-
type cells treated with vehicle for 5 days: 18.75%  9.49%; p 
0.05; **, P301L cells treated with A42 for 1 day: 64.66% 
12.93% pS422/HT7-positive cells; P301L cells treated with ve-
hicle for 1 day: 27.93%  5.60%; p  0.002; Mann-Whitney
U test).
To better characterize the role of Ser-422 in tau filament
formation, we mutated Ser-422 to alanine or glutamic acid and
expressed either P301L/S422A or P301L/S422E double mu-
tants both in undifferentiated and in neuronally differentiated
cells at similar levels as compared with the wild-type and
P301L single mutant cells (Fig. 1A). The Ser-422 mutations
were introduced into the P301L mutant and not into the wild-
type tau expression constructs because the P301L cells showed
the strongest phospho-Ser-422 staining. Next, we incubated
the undifferentiated cells for 5 days with A42 and fractionated
tau into the RAB fraction, the RIPA-soluble fraction, and the
FA-soluble fraction. In contrast to A42-treated P301L tau-
expressing cells, tau was not present in the FA fraction of
P301L/S422A and P301L/S422E extracts, indicating that mu-
tagenesis of Ser-422 blocked the A42-mediated decrease in the
solubility of tau (Fig. 6E).
FIG. 3. A42 does not cause increased transcription of tau
mRNA. After incubation with PBS for 5 days (gray), slight increases of
tau mRNA levels (as shown by Ct (cycle threshold) values for tau
compared with the reference gene GAPDH) are found for both mock-
and P301L-transfected cells, compared with time point t 0 (white).
These are statistically not significant (two-tailed Student’s t test; p 
0.38). After incubation with A42 for 5 days (black), levels are slightly
decreased in both cell types. These differences are again not statisti-
cally significant (two-tailed Student’s t test; p  0.14), demonstrating
that A42 does not cause increased tau transcription. In addition, this
analysis reveals 	60-fold higher tau mRNA levels in P301L compared
with mock-transfected cells (as shown by the lower Ct values).
FIG. 4. Generation of PHF-like tau filaments in cultured hu-
man neuroblastoma cells. Tau-expressing SH-SY5Y cells were incu-
bated for 5 days with aggregated A42 preparations, extracted with
sarkosyl, and protein extracts were analyzed by immunoelectron mi-
croscopy. A, a typical PHF extracted from an AD brain has a width of 20
nm and a periodicity of 80 nm. B and C, tau filaments extracted from
wild-type tau-expressing cells have a width of 20 nm and a periodicity
of 150–160 nm. To reveal the periodicity, part of the filament in panel
C is shown at a higher magnification in (C). D and E, filaments
extracted from undifferentiated P301L tau-expressing cells have a
width of 20 nm and a periodicity of 130–140 nm, resembling the nar-
row, twisted ribbons identified in human P301L carriers. Both types of
filaments are labeled with antibody Tau-5A6. Scale bar, 40 nm (A–C,
D–E), 20 nm (C).
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Finally, we determined whether treatments with A42 would
induce PHF-like tau filaments in either double mutant cell
line. We did not find any evidence for PHF-like tau filament
formation in the presence of the S422A or the S422E mutation
(Table I). Together, these data suggest an important role of
Ser-422 in A42-induced tau filament formation.
DISCUSSION
The results of this study show that A42 decreases the solu-
bility of tau and induces PHF-like tau filaments in a human
tissue culture system. A 5-day incubation with aggregated syn-
thetic A42 of SH-SY5Y neuroblastoma cells that had been
stably transfected with expression constructs encoding the
longest human tau isoform, with or without the pathogenic
FTDP-17 mutation P301L, caused a substantial amount of tau
to appear in the FA fraction. A quantitative TaqMan PCR
analysis of A42-treated cells did not reveal increased tau
mRNA synthesis, although increases below 1.5-fold would not
be detected by this method. Instead, the increased appearance
of tau in the FA fraction indicates a role of A42 in the biophys-
ical properties of tau that determine its solubility within cells.
However, we cannot exclude that A42 may also affect the
turnover rate of tau. The decreased solubility of tau in response
to exposure to A42 was also associated with the formation of
twisted tau filaments as shown by negative contrast electron
microscopy of sarkosyl protein extracts. These resembled the
PHF extracted from NFT in human neurodegenerative dis-
eases and are best described as narrow twisted ribbons (17).
This difference in periodicity to the PHF extracted from human
postmortem brains may be related to the known influence of
the ratio of 4-repeat to 3-repeat human tau. In comparison to
the 1:1 ratio in human brains (4), this ratio was high (above
10:1) in our experimental system.
The ultrastructural characteristics of abnormal filaments in
human neurodegenerative diseases vary with pathogenic mu-
tations (4, 5). We found that the PHF-like filaments extracted
from cells expressing P301L mutant tau had shorter periodici-
TABLE I
Tau filament formation
The data were obtained after 5 days of treatment with A42 prepa-
rations.
Undifferentiated Differentiated
PBS A42 PBS A42
Mock NDa ND No No
Wild-type tau No Yes No Yes
P301L tau No Yes No Yes
P301L/S422E tau No No No No
P301L/S422A tau No No No No
a ND, not determined
FIG. 5. Cryoelectron microscopy of ultra-thin sections. A and B,
undifferentiated wild-type tau-expressing cells were treated with A42
for 5 days, and cryosections were obtained and incubated with the
human tau-specific antibody, Tau-5A6, followed by a gold-labeled sec-
ondary antibody. Two sections obtained from A42-treated cells are
shown. As controls, untreated cells were included and the primary
antibody was omitted. Immunoelectron microscopy reveals many gold-
decorated aggregates in the cytoplasm of neurons that were treated
with A42. C, for a semiquantitative analysis, a cutoff of 15 gold parti-
cles was defined, and groups of gold particles were counted per cell in
A42-treated (f) compared with untreated cells (), revealing an in-
crease in the number of filamentous tau aggregates in A42-treated
cells. Scale bar, 300 nm (A), 200 nm (B).
FIG. 6. Role of the epitope Ser-422 of tau. A–C, immunocytochem-
istry of differentiated wild-type tau-expressing cells incubated for 5
days with A42 using the human tau-specific antibody HT7 (A, red) and
the pS422 antiserum specific for tau phosphorylated at Ser-422 (B,
green) shows the distribution of phosphorylated tau relative to total tau
(C, merge). D, wild-type tau-expressing cells require a treatment for 5
days with A42 (f) to increase the ratio of pS422-positive cells relative
to total tau-expressing, HT7-positive cells compared with vehicle-
treated cells (). In contrast, incubation of P301L-expressing cells with
A42 for 1 day already causes a more than 2-fold increase in the number
of pS422-positive cells. 200 cells were counted for each experimental
condition. Mann-Whitney U test: *, p  0.05 comparing A42-treated
wild-type cells with vehicle-treated wild-type cells, and **, p  0.002
comparing A42-treated P301L cells with vehicle-treated P301L cells.
The AT8 antibody directed against phosphorylated Ser-202/Thr-205
stains all HT7-positive cells, irrespective of A42 treatments (data not
shown). E, in contrast to P301L mutant tau-expressing cells, tau is not
present in the FA fraction of extracts obtained from A42-treated
P301L/S422A and P301L/S422E cells. Scale bar, 20 m (A–C).
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ties of 130–140 nm compared with wild-type tau filaments,
consistent with the fact that mutations can affect the pheno-
type of the tau filaments. For comparison, the twisted ribbons
in FTDP-17 patients carrying the P301L mutation have peri-
odicities of greater than 130 nm (4), whereas the tau filaments
in Drosophila generated by expression of human 4-repeat wild-
type tau have periodicities of 45 nm (20).
Our data are consistent with our previous results of A42-
induced PHF-like tau filament formation in transgenic mice
(9), but in contrast to the transgenic mice A42-induced PHF
formation in tissue culture also occurred with wild-type tau.
This may be related to the species difference and points to the
possibility that human cells in culture may be more susceptible
to the formation of abnormal tau filaments as compared with
murine cells in vivo. Fibrillar aggregates of tau were previously
observed in Chinese hamster ovary cells that had been trans-
fected with triple mutant tau expression constructs (21). In a
related study (22), combined treatments of SH-SY5Y cells with
okadaic acid and 4-hydroxynonenal induced 2–3-nm-wide
fibrillar tau polymers. The PHF-like filaments in our tissue
culture system clearly differed from both of the above in that
they were much longer, about 10 times wider, and had readily
identifiable twisted structures (Fig. 4). This difference could
well be related to the prolonged exposure to A42 in our exper-
iments, because we could not observe any filamentous struc-
tures for up to 2 days of exposure to A42 (Table I).
A semi-quantitative analysis of filament analysis by immu-
noelectron microscopy on ultra-thin cryosections of cells re-
vealed a significant increase in the number of tau aggregates in
A42-treated cells. The albeit-low number of aggregates in the
untreated group is not unexpected, because overexpression of
tau in itself is likely to cause some aggregation as has been
shown in vivo for wild-type or P301L mutant tau-expressing
mice in the absence of A42 (6, 7, 23).
The expression of P301L mutant tau in transgenic mice
showed that the presence of a pathogenic mutation is required
for both early and substantial tau filament and tangle forma-
tion; wild-type tau transgenic mice develop only a few tangles
at very old age, despite higher expression levels of the trans-
gene (7, 24). Obviously, in mice, the pathogenic mutation is
needed to catalyze the pathogenic conversion of tau, which is
not the case in our cellular model. Therefore, our cellular model
mimics more closely human sporadic AD, where tau filament
formation occurs in the absence of tau mutations and tau
overexpression. However, it has to be kept in mind that in
humans AD needs decades to develop, whereas in vitro patho-
logical changes have to be achieved within a few days or in vivo
within a few months, asking for high (and therefore unphysi-
ological) levels of tau expression.
Our data also imply that either the Ser-422 site of tau itself
or its phosphorylation are necessary, although not sufficient,
for tau filament formation. Despite the presence of the P301L
mutation that in humans and in tau transgenic mouse models
enhances tau filament formation, the S422A and S422E mu-
tants did not form tau filaments by incubating the cells with
A42. In transgenic mice expressing P301L tau, Ser-422, but
not the AT8 epitope Ser-202/Thr-205, was among the epitopes
that were selectively phosphorylated in response to A42 injec-
tions (9). A42 treatment did not cause increases in the num-
bers of AT8-positive cells because all HT7-positive tau-express-
ing cells were also AT8-positive, even in the absence of A42.
These findings are in agreement with those obtained in mice
(9). In contrast, incubation of P301L-expressing cells with A42
for only 1 day caused a more than 2-fold increase in the number
of pS422-positive cells compared with HT7-positive cells.
Mutagenesis of Ser-422 revealed that tau was not present in
the FA fraction of A42-treated P301L/S422A or P301L/S422E
cells, in contrast to A42-treated wild-type or P301L tau-ex-
pressing cells. Similarly, we did not find any evidence for PHF-
like tau filament formation in the presence of the S422A or the
S422E mutation, suggesting an important role of Ser-422 both
in the A42-induced decrease in tau solubility and in tau fila-
ment formation (Table I). The finding that mutating the serine
of epitope 422 to glutamic acid also precluded tau filament
formation was unexpected because the S422E modification was
designed to mimic the negative charge caused by phosphoryl-
ation of this site. Thus, the sole addition of a negative charge at
this site is not sufficient to induce the formation of PHF-like
tau filaments; coordinated phosphorylation at multiple resi-
dues, including Ser-422, may be required. Tau adopts distinct
conformations during sequential phosphorylation reactions,
and the AD-specific phosphoepitope AT100 can only be gener-
ated by a sequential phosphorylation of tau, initially by glyco-
gen synthase kinase-3 followed by protein kinase A, indicat-
ing that prephosphorylation at particular sites can alter the
conformation and prevent phosphorylation at other sites (25).
An alternative explanation is provided by the fact that Ser-422
is located next to a putative caspase-3 cleavage site at position
421 and that altered caspase cleavage is involved in the rates of
filament formation (26–28).
CONCLUSION
In conclusion, we established a tissue culture system for the
generation of bona fide PHF-like filaments that closely resem-
bled those extracted from brains of AD patients. The results
provided by this system are compatible with an important role
of A42 in the generation of NFT in AD, and with a pivotal, yet
not exclusive, role of the Ser-422 epitope of tau in tau fibrillo-
genesis. Our data imply that either the Ser-422 site itself or its
phosphorylation are necessary, but not sufficient, for tau fila-
ment formation. PHF-like tau filament formation was achieved
within 5 days, much faster than in current transgenic mouse
models (8, 9). Therefore, this culture system will be useful to
map phosphoepitopes of tau involved in PHF formation and to
identify and characterize modifiers of the tau pathology. Fur-
ther adaptation of the system may allow the screening and
validation of compounds designed to prevent PHF formation.
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